news.google.com· FiercePharma·· 21 hours agoPickScore63
Bayer's Nubeqa scores phase 3 win in high-risk prostate cancer - Fierce Pharma
In brief
FiercePharma reports that Bayer's Nubeqa (darolutamide) achieved positive results in a phase 3 trial in high-risk prostate cancer. The original article provides only the headline and discloses no key data such as the trial name, sample size, hazard ratio, or confidence intervals.
Why it matters
Reports a phase 3 result for a named drug without key trial data.
Source: news.google.com · news.google.com